Waverley Pharma First Half 2024 Earnings: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)
Waverley Pharma (CVE:WAVE) First Half 2024 Results
Key Financial Results
- Net loss: CA$609.0k (loss widened by 4.9% from 1H 2023).
- CA$0.011 loss per share (in line with 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Waverley Pharma's share price is broadly unchanged from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 6 warning signs for Waverley Pharma that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Waverley Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:WAVE
Waverley Pharma
A biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom.
Medium-low and slightly overvalued.
